167 related articles for article (PubMed ID: 2189508)
1. Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia.
Hauch M; Gazzola MV; Small T; Bordignon C; Barnett L; Cunningham I; Castro-Malaspinia H; O'Reilly RJ; Keever CA
Blood; 1990 Jun; 75(11):2250-62. PubMed ID: 2189508
[TBL] [Abstract][Full Text] [Related]
2. Autologous activated natural killer cells suppress primitive chronic myelogenous leukemia progenitors in long-term culture.
Cervantes F; Pierson BA; McGlave PB; Verfaillie CM; Miller JS
Blood; 1996 Mar; 87(6):2476-85. PubMed ID: 8630414
[TBL] [Abstract][Full Text] [Related]
3. CD56+bright and CD56+dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis.
Pierson BA; Miller JS
Blood; 1996 Sep; 88(6):2279-87. PubMed ID: 8822949
[TBL] [Abstract][Full Text] [Related]
4. Interleukin 2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients. I. Feasibility of LAK generation in adult patients with active disease and in remission.
Adler A; Chervenick PA; Whiteside TL; Lotzová E; Herberman RB
Blood; 1988 Mar; 71(3):709-16. PubMed ID: 3257887
[TBL] [Abstract][Full Text] [Related]
5. Induction of in vitro graft-versus-leukemia activity following bone marrow transplantation for chronic myeloid leukemia.
Mackinnon S; Hows JM; Goldman JM
Blood; 1990 Nov; 76(10):2037-45. PubMed ID: 2242425
[TBL] [Abstract][Full Text] [Related]
6. Generation of activated natural killer (A-NK) cells in patients with chronic myelogenous leukaemia and their role in the in vitro disappearance of BCR/abl-positive targets.
Silla LM; Pincus SM; Locker JD; Glover J; Elder EM; Donnenberg AD; Nardi NB; Bryant J; Ball ED; Whiteside TL
Br J Haematol; 1996 May; 93(2):375-85. PubMed ID: 8639431
[TBL] [Abstract][Full Text] [Related]
7. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
[TBL] [Abstract][Full Text] [Related]
8. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
[TBL] [Abstract][Full Text] [Related]
9. Adherent lymphokine-activated killer cells in chronic myelogenous leukemia: a benign cell population with potent cytotoxic activity.
Verfaillie C; Miller W; Kay N; McGlave P
Blood; 1989 Aug; 74(2):793-7. PubMed ID: 2473805
[TBL] [Abstract][Full Text] [Related]
10. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice.
Hoyle C; Bangs CD; Chang P; Kamel O; Mehta B; Negrin RS
Blood; 1998 Nov; 92(9):3318-27. PubMed ID: 9787169
[TBL] [Abstract][Full Text] [Related]
11. Induction of a syngeneic graft-versus-leukemia effect following bone marrow transplantation for chronic myeloid leukemia.
Mackinnon S; Hows JM; Goldman JM
Leukemia; 1990 Apr; 4(4):287-91. PubMed ID: 2366584
[TBL] [Abstract][Full Text] [Related]
12. The role of autologous natural killer cells in chronic myelogenous leukemia.
Pierson BA; Miller JS
Leuk Lymphoma; 1997 Nov; 27(5-6):387-99. PubMed ID: 9477121
[TBL] [Abstract][Full Text] [Related]
13. BCR-ABL does not prevent apoptotic death induced by human natural killer or lymphokine-activated killer cells.
Roger R; Issaad C; Pallardy M; Léglise MC; Turhan AG; Bertoglio J; Bréard J
Blood; 1996 Feb; 87(3):1113-22. PubMed ID: 8562937
[TBL] [Abstract][Full Text] [Related]
14. Natural killer (NK) cell immunodeficiency in patients with chronic myelogenous leukemia. II. Successful cloning and amplification of natural killer cells.
Fujimiya Y; Chang WC; Bakke A; Horwitz D; Pattengale PK
Cancer Immunol Immunother; 1987; 24(3):213-20. PubMed ID: 3496152
[TBL] [Abstract][Full Text] [Related]
15. High lytic activity against human leukemia cells after activation of allogeneic NK cells by IL-12 and IL-2.
Uharek L; Zeis M; Glass B; Steinmann J; Dreger P; Gassmann W; Schmitz N; Müller-Ruchholtz W
Leukemia; 1996 Nov; 10(11):1758-64. PubMed ID: 8892679
[TBL] [Abstract][Full Text] [Related]
16. Diminished A-LAK cytotoxicity and proliferation accompany disease progression in chronic myelogenous leukemia.
Verfaillie C; Kay N; Miller W; McGlave P
Blood; 1990 Jul; 76(2):401-8. PubMed ID: 1695114
[TBL] [Abstract][Full Text] [Related]
17. Origin and function of adherent lymphokine activated killer cells in patients with chronic myeloid leukaemia who relapse following bone marrow transplantation.
Mackinnon S; Bungey J; Chase A; Paulsen W; Hows JM; Goldman JM
Br J Haematol; 1991 Jan; 77(1):60-5. PubMed ID: 1998598
[TBL] [Abstract][Full Text] [Related]
18. Potential of autologous immunologic effector cells for bone marrow purging in patients with chronic myeloid leukemia.
Scheffold C; Brandt K; Johnston V; Lefterova P; Degen B; Schöntube M; Huhn D; Neubauer A; Schmidt-Wolf IG
Bone Marrow Transplant; 1995 Jan; 15(1):33-9. PubMed ID: 7538001
[TBL] [Abstract][Full Text] [Related]
19. Natural killer cell immunodeficiency in patients with chronic myelogenous leukemia. IV. Interleukin-1 deficiency, gamma-interferon deficiency and the restorative effects of short-term culture in the presence of interleukin-2 on natural killer cytotoxicity, natural killer-target binding and production of natural killer cytotoxic factor.
Chang WC; Hsiao MH; Pattengale PK
Nat Immun Cell Growth Regul; 1991; 10(2):57-70. PubMed ID: 1881400
[TBL] [Abstract][Full Text] [Related]
20. Susceptibility of autologous target cells to lysis by lymphokine-activated effectors from interferon-alpha-treated chronic myelogenous leukaemia patients.
Pawelec G; Ehninger G; Schmidt H; Müller C; Bühring HJ; Reutter M; Busch FW
Cancer Immunol Immunother; 1990; 32(3):167-72. PubMed ID: 2289210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]